#THANKYOUNHS

Thank you to all of our NHS staff and support workers and carers for everything they do on the frontline to serve our patients. For further information on Janssen’s response to COVID-19 including information on supply, please visit our website JJ Coronavirus Update.

 

PATIENT RESOURCES

In order to support your conversations with your Imbruvica® (ibrutinib) patients, we would like to offer some digital Imbruvica patient support packs for your Chronic Lymphocytic Leukaemia (CLL), Mantle Cell Lymphoma (MCL) and Waldenström's Macroglobulinaemia (WM) patients.

These are available for download below:

CLL Patient Information Booklet

 

DOWNLOAD RESOURCE

MCL Patient Information Booklet

DOWNLOAD RESOURCE

WM Patient Information Booklet

 

DOWNLOAD RESOURCE

 

QUICK INFORMATION

Our simple animation breaks down the key information for the switch from capsule to tablet.

Imbruvica® (ibrutinib) prescribing information & adverse events reporting can be found here.

Post-prescription information for patients is available in both hard copy and digital PDF to help clarify the transition between formulations. 

 

 

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Janssen-Cilag Limited on 01494 567447 or at [email protected].

 

CLL - Chronic lymphocytic leukaemia
MCL - Mantle cell lymphoma
WM - Waldenström's macroglobulinaemia

Date of preparation: July 2020
Item code: CP-162667

 

Date of preparation: July 2020
Item code: CP-162667